Global Cancer Vaccines Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Technology (Dendritic Cells (DC), Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole-Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines, Others), By Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), By Application (Cervical Cancer, Prostate Cancer, Others), By End-Use (Pediatrics, Adults), And By Geography - Forecasts From 2022 To 2027

  • Published : Apr 2022
  • Report Code : KSI061612163
  • Pages : 135

The global cancer vaccine market is expected to grow at a compound annual growth rate of 13.08% over the forecast period to reach a market size of US$13.068 billion in 2027, from US$5.527 billion in 2020. Cancer vaccines are used to provide treatment or protection from cancer, which classifies them into prevention and treatment cancer vaccines. They are a type of immunotherapy that destroys cancer cells, stops the growth of tumors, and also helps in preventing any such cases in the body in the future.

Market Trend

The increased cases of cancer globally due to unhealthy living practises is one of the prime causes behind the growth of the cancer vaccine market. Also, the increasing research on inherited cancer and a definitive result in the field are expected to hold a large market for the growth of cancer vaccines. Cancer vaccines have been approved for Human Papilloma Virus (HPV) and Hepatitis B (HBV) by the FDA, which can provide significant growth to the market in the coming years.

Cancer vaccines are known for causing severe after-symptoms in the body, which may result in a constraint in the growth of the cancer vaccine market. Also, the increasing research for natural, plant-based, Ayurveda therapy for the treatment of cancer is expected to create some hurdles for the growth of the market in the future. The loss of immunity with age in the elderly population can also serve as a threat to the market’s growth due to increased chances of low immune response after the vaccination. Besides that, the high price associated with cancer vaccines can also hamper their market growth.

Growth Factors

  • Increasing cases of  cancer worldwide:

The change in lifestyle habits, followed by the increasing consumption of unhealthy products like tobacco, cigarettes, and exposure to radiation and viruses, has been increasing the global number of cancer patients worldwide. According to the WHO,  cancer is the leading cause of death worldwide and accounted for nearly 10 million deaths in 2020, which was higher than the 2018 data of 9.6 million deaths. Of these, lung cancer caused around 1.8 million deaths, cancer in the colon and rectum was responsible for 935,000 deaths, liver cancer caused 830,000 deaths, stomach cancer caused around 769,000 deaths, and breast cancer caused 685,000 deaths. The increasing rate of cancer mortality has put a major focus on the development of cancer vaccines.

  • Family Cancer Syndromes:

Certain types of cancer seem to run in families, which can be due to the same exposure that increases cancer risk, like smoking and family running obesity, But, in some cases, like inherited cancer, an abnormal gene is passed along from one generation to another that can lead to cancer. According to the American Cancer Society, around 5%-10% of all cancers result directly from mutations. Increasing research and a definitive result in this field are expected to hold growth prospects for the development of cancer vaccines in the upcoming years.


Increasingly Elderly Population:  One of the major restraints on the cancer vaccine market is the growing elderly population, which is accompanied by low immunity in people. This is expected to serve as a constraint for the market’s growth as a weak immune system hampers the immune response of the body and thus reduces the chances of an effective response by the cancer vaccines in the body. UN  data,  suggests that by 2050, around 1 in 6 people in the world will be over the age of 65, up from 1 in 11 in 2019.

  • The side effects associated with cancer vaccines can increase the demand for Ayurveda treatment:

Cancer Treatment Vaccines can cause various side effects, which depend on various factors like the type of cancer, how advanced it is the type of vaccine treatment, the dosage, etc. The National Cancer Institute has laid down a list of side effects like fatigue, headache, trouble breathing, weakness, chills, fever, low and high blood pressure, and certain allergic reactions as well. Also, Sipuleucel-T can trigger strokes in human bodies. Fear of such side effects, along with their severity, may hamper the growth of the cancer vaccine market.

This is expected to pave the way for Ayurveda and natural therapies in cancer treatment, which could pose a threat to the growth of the cancer vaccine market. Although there is no strict evidence or approval that Ayurveda as a system of medicine can treat cancer, researchers have found that yoga, meditation, and Ayurveda approaches are helpful as complementary therapies in cancer treatment. Besides that, the National Center for Biotechnology Institution that comes under the U.S. National Library of Medicine has laid down a list of certain plants like Flacourtia romantchi, Moringa oleifera, Ficus bengalensis, Semecarpus Anacardium, etc. that have scientific evidence of anticancer properties.

The COVID-19 Pandemic's Impact on the Cancer Vaccine Market: With the onset of the coronavirus, the prime motive of governments across the globe shifted towards controlling the spread of the COVID virus. This severely hampered the growth of the cancer vaccine,  market as the healthcare units, pharmaceutical companies, and their research and development work shifted towards the development of COVIDvaccine and this created a major restraint for the growth of cancer vaccine development.

Global Cancer Vaccines Market Scope:

Report Metric Details
 Market size value in 2020  US$5.527 billion
 Market size value in 2027  US$13.068 billion
 Growth Rate  CAGR of 13.08% from 2020 to 2027
 Base year  2020
 Forecast period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments covered  Technology, Type, Application, End-Use, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered AstraZeneca plc, GlaxoSmithKline plc., Merck & Co., Inc., Pfizer Inc., Moderna Inc., OSE Therapeutics, Nouscom, OncBioMune Pharmaceuticals Inc., Sanofi S.A., Bristol-Myers Squibb
 Customization scope  Free report customization with purchase


Market Segmentation:

  • By Technology
    • Dendritic Cells (DC) Cancer Vaccines
    • Recombinant Cancer Vaccines
    • Antigen/Adjuvant Cancer Vaccines
    • Whole-Cell Cancer Vaccines
    • Viral Vector & DNA Cancer Vaccines
    • Others
  • By Type
    • Preventive Cancer Vaccines
    • Therapeutic Cancer Vaccines
  • By Application
    • Cervical Cancer
    • Prostate Cancer
    • Others
  • By End-Use
    • Pediatrics
    • Adults
  • By Geography
    • North America
      • USA
      • Canada
      • México
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • U.K.
      • Germany
      • France
      • Others
    • Middle East and Africa
      •  UAE
      • South Africa
      • Israel
      • Saudi Arabia
      • Others
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • Taiwan
      • South Korea
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the cancer vaccines market size by 2027?
A1. The global cancer vaccines market is expected to reach a total market size of US$13.068 billion by 2027.

Q2. What is the size of the global cancer vaccines market?
A2. Cancer Vaccines Market was valued at US$13.068 billion in 2020.  

Q3. What are the growth prospects for the cancer vaccines market?
A3. The cancer vaccines market is expected to grow at a CAGR of 13.08% over the forecast period. 

Q4. What factors are anticipated to drive the cancer vaccines market growth?
A4. The increased cases of cancer globally due to unhealthy living practices is one of the prime causes behind the growth of the cancer vaccines market.

Q5. How is the global cancer vaccines market segmented?
A5. The cancer vaccines market has been segmented by technology, type, application, end-use, and geography.

1.1. Market Definition
1.2. Market Segmentation

2.1. Research Data
2.2. Assumptions

3.1. Research Highlights

4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5.1. Introduction
5.2. Dendritic Cells (DC) Cancer Vaccines
5.3. Recombinant Cancer Vaccines
5.4. Antigen/Adjuvant Cancer Vaccines
5.5. Whole-Cell Cancer Vaccines
5.6. Viral Vector & DNA Cancer Vaccines
5.7. Others

6.1. Introduction
6.2. Preventive Cancer Vaccines
6.3. Therapeutic Cancer Vaccines

7.1. Introduction
7.2. Cervical Cancer
7.3. Prostate Cancer
7.4. Others

8.1. Introduction
8.2.  Pediatrics
8.3. Adults

9.1.  Introduction
9.2.  North America
9.2.1. USA
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Others
9.5.  Middle East and Africa
9.5.1. UAE
9.5.2. South Africa
9.5.3. Israel
9.5.4. Saudi Arabia
9.5.5. Others
9.6. Asia Pacific
9.6.1. China
9.6.2. Japan
9.6.3. India
9.6.4. Australia
9.6.5. Taiwan
9.6.6. South Korea
9.6.7. Others

10.1. Major Players and Strategy Analysis
10.2.  Emerging Players and Market Lucrativeness
10.3.  Mergers, Acquisitions, Agreements, and Collaborations
10.4.  Vendor Competitiveness Matrix

11.1. AstraZeneca plc
11.2. GlaxoSmithKline plc.
11.3. Merck & Co., Inc.
11.4. Pfizer Inc.
11.5. Moderna Inc.
11.6. OSE Therapeutics
11.7. Nouscom
11.8. OncBioMune Pharmaceuticals Inc.
11.9. Sanofi S.A.
11.10. Bristol-Myers Squibb

AstraZeneca plc

GlaxoSmithKline plc.

Merck & Co., Inc.

Pfizer Inc.

Moderna Inc.

OSE Therapeutics


OncBioMune Pharmaceuticals Inc.

Sanofi S.A.

Bristol-Myers Squibb